Poseida Therapeutics WKN: A2PEYK ISIN: US73730P1084
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
k.A. % HL
Intervall: k.A.
High: k.A.
Low: k.A.
Börse: k.A.
Anzeige
Alles ab 0 Euro pro Order. Dauerhaft.


Schorsch11
vom 22.08.20 23:32 Uhr
https://www.fiercebiotech.com/biotech/poseida-shares-plunge-after-death-solid-car-t-trial-hold

Schorsch11
vom 22.08.20 23:26 Uhr
Net Losses
Net losses were $30.4 million and $59.2 million for the three and six months ended June 30, 2020, respectively, and $28.6 million and $42.0 million for the three and six months ended June 30, 2019, respectively.
Cash Position
As of June 30, 2020, we had cash, cash equivalents and short-term investments of $167.1 million. Net proceeds from the Company's IPO, which closed in July 2020, were $204.8 million

Schorsch11
vom 22.08.20 20:30 Uhr
Rebound-Kandidat:
Poseida Therapeutics, Inc. (NASDAQ:PSTX) shares closed the week down 34% to $8.61 on news its Phase 1 trial of P-PSMA-101 in metastatic castrate resistant prostate cancer patients has been placed on clinical hold due to a patient death arising from hepatic failure.
|
Kommentare | ||
---|---|---|---|
1 | Hauptdiskussion |
Kursdetails
Geld (bid) | 0,00 (0) |
---|---|
Brief (ask/offer) | 0,00 (0) |
Spread | - |
Geh. Stück | 0 |
Eröffnung | 2,09 |
Vortag | 2,09 |
Tageshoch | 2,20 |
Tagestief | 2,01 |
52W Hoch | 9,38 |
52W Tief | 1,75 |
Tagesvolumen
in EUR gehandelt | 200 Stk |
---|---|
in USD gehandelt | 115 Tsd. Stk |
Gesamt | 116 Tsd. Stk |
Anzeige

Der Broker von Deutschlands größter Finanzcommunity
Meldungen
- Putin warnt vor neuen Nato-Beitritten
- SMA Solar (S92) korrigieren, Nordex (NDX1) behauptet; Rivian (RIVN) und Tesla (TL0) tiefrot
- Silver X Mining Corp: Silver X meldet aktuelle Informationen zur Betriebstätigkeit im April
- Kein klarer Trend - Sorge vor Wachstumsabkühlung
- Osten gleichbehandeln - 'Klare Perspektive' für Leuna
Geld/Brief Kurse
Börse | Geld | Brief | Zeit | Volumen | Kurs |
---|---|---|---|---|---|
Frankfurt | 2,06 | 2,14 | 1652685360 09:16 | 2,06 EUR | |
Düsseldorf | 2,04 | 2,16 | 1652722252 19:30 | 1,98 EUR | |
München | 2,08 | 2,10 | 1652680891 08:01 | 2,06 EUR | |
Stuttgart | 2,04 | 2,14 | 1652723258 19:47 | 2,02 EUR | |
Nasdaq | 2,18 | 2,19 | 1652729462 21:31 | 115.344 Stk | 2,18 USD |
AMEX | 1652486400 14. May | 100 Stk | 2,17 USD | ||
Tradegate | 2,06 | 2,08 | 1652692376 11:12 | 200 Stk | 2,12 EUR |
London | 1652281992 11. May | 1,98 USD | |||
Gettex | 2,04 | 2,12 | 1652730181 21:43 | 2,06 EUR | |
Baader Bank | 2,04 | 2,12 | 1652730084 21:41 | 2,08 EUR | |
TTMzero RT | 1652730315 21:45 | 2,07 EUR | ges. 115.644 Stk |
Realtime / Verzögert
Börsennotierung
Marktkapitalisierung in EUR |
---|
385,6 Mio. |
Anzahl der Aktien |
62,7 Mio. |
Grundlegende Daten zur Poseida Therapeutics Aktie
Finanzdaten | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e |
---|---|---|---|---|---|---|---|
KUV | - | - | - | - | - | - | - |
Ergebnis je Aktie (bereinigt) | - | - | - | - | - | - | - |
Cashflow | - | - | - | - | - | - | - |
Eigenkapitalquote | - | - | - | - | - | - | - |
Verschuldungsgrad | - | - | - | - | - | - | - |
Eigenkapitalrendite | - | - | - | - | - | - | - |
Gesamtkapitalrendite | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT | - | - | - | - | - | - | - |
Fundamentaldaten | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e |
KCV | - | - | - | - | - | - | - |
Dividendenrendite | - | - | - | - | - | - | - |
Kurs-Gewinn-Verhältnis (KGV) | - | - | - | - | - | - | - |
Dividende je Aktie | - | - | - | - | - | - | - |
Bilanzdaten | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e |
Netto-Provisionsüberschuss | - | - | - | - | - | - | - |
Umsatzerlöse | - | - | - | - | - | - | - |
Ergebnis vor Steuern | - | - | - | - | - | - | - |
Steuern | - | - | - | - | - | - | - |
Ausschüttungssumme | - | - | - | - | - | - | - |
Nettoverzinsung | - | - | - | - | - | - | - |
Zinsertrag | - | - | - | - | - | - | - |
Gesamtertrag | - | - | - | - | - | - | - |